|Bid||76.74 x 1100|
|Ask||76.75 x 800|
|Day's Range||76.51 - 77.26|
|52 Week Range||68.44 - 83.78|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||34.99|
|Earnings Date||Oct 28, 2021|
|Forward Dividend & Yield||2.60 (3.38%)|
|Ex-Dividend Date||Sep 14, 2021|
|1y Target Est||93.02|
Merck (NYSE: MRK) recently won U.S. Food and Drug Administration approval for its pneumococcal vaccine. Pfizer (NYSE: PFE) currently dominates the pneumococcal vaccine market, with its Prevenar 13 generating nearly $6 billion in sales last year. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss whether or not Merck can beat Pfizer in this multibillion-dollar vaccine market.
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.